HER2-Positive Breast Cancer, 1st Edition
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Key Features
- Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
- Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
- Includes a timely section on innovative future therapies.
Author Information
ISBN Number | 9780323581226 |
---|---|
Main Author | By Sara Hurvitz, MD and Kelly McCann |
Copyright Year | 2019 |
Edition Number | 1 |
Format | Book |
Trim | 191w x 235h (7.50" x 9.25") |
Illustrations | Approx. 100 illustrations (100 in full color) |
Imprint | Elsevier |
Page Count | 264 |
Publication Date | 15 Aug 2018 |
Stock Status | IN STOCK - This may take up to 5 business days to ship |
Background/testing
1. The HER2 alteration in breast cancer
2. HER2 testing in the era of changing guidelines
Advanced Disease
3. Optimal first-line treatment of HER2+ advanced disease
4. Second line therapy and beyond
5. HER2+ CNS metastases
Therapeutics
6. Neoadjuvant therapy
7. Adjuvant therapy
8. Outcomes based on HR status in early stage disease
9. De-escalation of therapy for small tumor
Toxicity considerations
10. Cardiac toxicity of HER2-targeted regimens
11. Non-cardiac toxicity of HER2-targeted therapy
Therapies on the horizon
12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)
13. Harnessing the immune system in HER2+ disease
14. Biosimilars
Related Products
-
30% OFF BookNolte's The Human Brain in Photographs and Diagrams
Todd W. Vanderah
Jan 2019
Special Price $44.79 $63.99 -
35% OFF Book
-
30% OFF Book
-
35% OFF Book
-
35% OFF Flash Cards
-
35% OFF Online ResourceNetter's Dissection Video Modules (Retail Access Card)
University of North Carolina Chapel Hill and Frank H. Netter
Oct 2015
Special Price $117.64 $180.99 -
35% OFF Book
-
35% OFF Flash Cards
-
35% OFF Flash Cards
-
35% OFF Book